Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis
Background. The results of previous clinical trials evaluating the efficacy and safety of recombinant human interleukin-2 (rhuIL-2) for adult patients with pulmonary tuberculosis showed inconsistent results. Accordingly, a comprehensive systematic review and meta-analysis was performed. Methods. Rel...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Tropical Medicine |
| Online Access: | http://dx.doi.org/10.1155/2022/5071816 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849405388019990528 |
|---|---|
| author | Lina Sheng Xiaofei Li Fangbin Weng Shuang Wu Yongxin Chen Lianqing Lou |
| author_facet | Lina Sheng Xiaofei Li Fangbin Weng Shuang Wu Yongxin Chen Lianqing Lou |
| author_sort | Lina Sheng |
| collection | DOAJ |
| description | Background. The results of previous clinical trials evaluating the efficacy and safety of recombinant human interleukin-2 (rhuIL-2) for adult patients with pulmonary tuberculosis showed inconsistent results. Accordingly, a comprehensive systematic review and meta-analysis was performed. Methods. Relevant randomized controlled trials (RCTs) were retrieved by searching the PubMed, Embase, Cochrane’s Library, Web of Science, Wanfang, and CNKI databases. A random-effects model was used to combine the results. Results. 18 RCTs with 2630 patients were included in this meta-analysis. Pooled results showed that adjunctive rhuIL-2 significantly increased the odds of sputum culture conversion to negative (risk ratio [RR]: 1.27, 95% CI: 1.09 to 1.47, p=0.002, I2 = 80%), sputum smear conversion to negative (RR: 1.35, 95% CI: 1.17 to 1.57, p<0.001, I2 = 83%), radiographic focus absorption (RR: 1.17, 95% CI: 1.06 to 1.30, p=0.002, I2 = 72), and cavity closure (RR: 1.24, 95% CI: 1.09 to 1.40, p<0.001, I2 = 23). The use of rhuIL-2 was not related to any severe adverse events which led to discontinuation of the treatment. Results showed that rhuIL-2 was related to an increased risk of fever (RR: 2.46, 95% CI: 1.29 to 4.70, p=0.006, I2 = 0%). The incidence of other adverse events, such as musculoskeletal pain, hepatic injury, and renal toxicity, was not significantly different between groups (p all >0.05). Conclusions. rhuIL-2 is an effective adjunctive immunotherapy for patients with pulmonary tuberculosis. |
| format | Article |
| id | doaj-art-4e37c08fad02471dacf8b7066a62dfe3 |
| institution | Kabale University |
| issn | 1687-9694 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Tropical Medicine |
| spelling | doaj-art-4e37c08fad02471dacf8b7066a62dfe32025-08-20T03:36:41ZengWileyJournal of Tropical Medicine1687-96942022-01-01202210.1155/2022/5071816Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-AnalysisLina Sheng0Xiaofei Li1Fangbin Weng2Shuang Wu3Yongxin Chen4Lianqing Lou5Department of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesDepartment of Infectious DiseasesBackground. The results of previous clinical trials evaluating the efficacy and safety of recombinant human interleukin-2 (rhuIL-2) for adult patients with pulmonary tuberculosis showed inconsistent results. Accordingly, a comprehensive systematic review and meta-analysis was performed. Methods. Relevant randomized controlled trials (RCTs) were retrieved by searching the PubMed, Embase, Cochrane’s Library, Web of Science, Wanfang, and CNKI databases. A random-effects model was used to combine the results. Results. 18 RCTs with 2630 patients were included in this meta-analysis. Pooled results showed that adjunctive rhuIL-2 significantly increased the odds of sputum culture conversion to negative (risk ratio [RR]: 1.27, 95% CI: 1.09 to 1.47, p=0.002, I2 = 80%), sputum smear conversion to negative (RR: 1.35, 95% CI: 1.17 to 1.57, p<0.001, I2 = 83%), radiographic focus absorption (RR: 1.17, 95% CI: 1.06 to 1.30, p=0.002, I2 = 72), and cavity closure (RR: 1.24, 95% CI: 1.09 to 1.40, p<0.001, I2 = 23). The use of rhuIL-2 was not related to any severe adverse events which led to discontinuation of the treatment. Results showed that rhuIL-2 was related to an increased risk of fever (RR: 2.46, 95% CI: 1.29 to 4.70, p=0.006, I2 = 0%). The incidence of other adverse events, such as musculoskeletal pain, hepatic injury, and renal toxicity, was not significantly different between groups (p all >0.05). Conclusions. rhuIL-2 is an effective adjunctive immunotherapy for patients with pulmonary tuberculosis.http://dx.doi.org/10.1155/2022/5071816 |
| spellingShingle | Lina Sheng Xiaofei Li Fangbin Weng Shuang Wu Yongxin Chen Lianqing Lou Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis Journal of Tropical Medicine |
| title | Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
| title_full | Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
| title_fullStr | Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
| title_full_unstemmed | Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
| title_short | Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
| title_sort | efficacy and safety of adjunctive recombinant human interleukin 2 for patients with pulmonary tuberculosis a meta analysis |
| url | http://dx.doi.org/10.1155/2022/5071816 |
| work_keys_str_mv | AT linasheng efficacyandsafetyofadjunctiverecombinanthumaninterleukin2forpatientswithpulmonarytuberculosisametaanalysis AT xiaofeili efficacyandsafetyofadjunctiverecombinanthumaninterleukin2forpatientswithpulmonarytuberculosisametaanalysis AT fangbinweng efficacyandsafetyofadjunctiverecombinanthumaninterleukin2forpatientswithpulmonarytuberculosisametaanalysis AT shuangwu efficacyandsafetyofadjunctiverecombinanthumaninterleukin2forpatientswithpulmonarytuberculosisametaanalysis AT yongxinchen efficacyandsafetyofadjunctiverecombinanthumaninterleukin2forpatientswithpulmonarytuberculosisametaanalysis AT lianqinglou efficacyandsafetyofadjunctiverecombinanthumaninterleukin2forpatientswithpulmonarytuberculosisametaanalysis |